inclusion criteria: 1. adult males and females ≥18 years and ≤80 years of age at the time of screening. 2. are hospitalised during the screening period with duration of hospitalisation prior to randomisation ≤48 hours. 3. have a diagnosis of covid-19 based on symptoms onset and positive sars-cov-2 rt-pcr test from nasopharyngeal swab. 4. viral load ≤ 30 ct 5. have at least one (1) of the following: 1. radiographic pulmonary infiltrates (ct scan), and/or 2. clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air, and/or 3. requirement for supplemental oxygen. 6. if female, of non-childbearing potential or if of childbearing potential, be willing to commit to either sexual abstinence or use of at least 2 medically accepted, effective methods of birth control from screening through 2 months after last alisporivir dose. 7. if male, a willingness to refrain from donating sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, a willingness to use a condom in addition to having the female partner use a highly effective method of birth control from screening through 4 months after last alisporivir dose. 8. willing and able to provide written informed consent. 9. willing to comply with all study assessments and adhere to the protocol schedule. 10. has an affiliation with a social security system.

inclusion criteria: 1. adult males and females ≥18 years and ≤80 years of age at the time of screening. 2. are hospitalised during the screening period with duration of hospitalisation prior to randomisation ≤48 hours. 3. have a diagnosis of covid-19 based on symptoms onset and positive sars-cov-2 rt-pcr test from nasopharyngeal swab. 4. viral load ≤ 30 ct 5. have at least one (1) of the following: 1. radiographic pulmonary infiltrates (ct scan), and/or 2. clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air, and/or 3. requirement for supplemental oxygen. 6. if female, of non-childbearing potential or if of childbearing potential, be willing to commit to either sexual abstinence or use of at least 2 medically accepted, effective methods of birth control from screening through 2 months after last alisporivir dose. 7. if male, a willingness to refrain from donating sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, a willingness to use a condom in addition to having the female partner use a highly effective method of birth control from screening through 4 months after last alisporivir dose. 8. willing and able to provide written informed consent. 9. willing to comply with all study assessments and adhere to the protocol schedule. 10. has an affiliation with a social security system.

inclusion criteria: adult males and females ≥18 years and ≤80 years of age at the time of screening. are hospitalised during the screening period with duration of hospitalisation prior to randomisation ≤48 hours. have a diagnosis of covid-19 based on symptoms onset and positive sars-cov-2 rt-pcr test from nasopharyngeal swab. viral load ≤ 30 ct have at least one (1) of the following: radiographic pulmonary infiltrates (ct scan), and/or clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air, and/or requirement for supplemental oxygen. if female, of non-childbearing potential or if of childbearing potential, be willing to commit to either sexual abstinence or use of at least 2 medically accepted, effective methods of birth control from screening through 2 months after last alisporivir dose. if male, a willingness to refrain from donating sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, a willingness to use a condom in addition to having the female partner use a highly effective method of birth control from screening through 4 months after last alisporivir dose. willing and able to provide written informed consent. willing to comply with all study assessments and adhere to the protocol schedule. has an affiliation with a social security system.

inclusion criteria: adult males and females ≥18 years and ≤80 years of age at the time of screening. are hospitalised during the screening period with duration of hospitalisation prior to randomisation ≤48 hours. have a diagnosis of covid-19 based on symptoms onset and positive sars-cov-2 rt-pcr test from nasopharyngeal swab. viral load ≤ 30 ct have at least one (1) of the following: radiographic pulmonary infiltrates (ct scan), and/or clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air, and/or requirement for supplemental oxygen. if female, of non-childbearing potential or if of childbearing potential, be willing to commit to either sexual abstinence or use of at least 2 medically accepted, effective methods of birth control from screening through 2 months after last alisporivir dose. if male, a willingness to refrain from donating sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, a willingness to use a condom in addition to having the female partner use a highly effective method of birth control from screening through 4 months after last alisporivir dose. willing and able to provide written informed consent. willing to comply with all study assessments and adhere to the protocol schedule. has an affiliation with a social security system.

inclusion criteria: 1. adult males and females ≥18 years and ≤80 years of age at the time of screening. 2. are hospitalised during the screening period with duration of hospitalisation prior to randomisation ≤48 hours. 3. have a diagnosis of covid-19 based on symptoms onset and positive sars-cov-2 rt-pcr test from nasopharyngeal swab. 4. viral load ≤ 30 ct 5. have at least one (1) of the following: 1. radiographic pulmonary infiltrates (ct scan), and/or 2. clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air, and/or 3. requirement for supplemental oxygen. 6. if female, of non-childbearing potential or if of childbearing potential, be willing to commit to either sexual abstinence or use of at least 2 medically accepted, effective methods of birth control from screening through 2 months after last alisporivir dose. 7. if male, a willingness to refrain from donating sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, a willingness to use a condom in addition to having the female partner use a highly effective method of birth control from screening through 4 months after last alisporivir dose. 8. willing and able to provide written informed consent. 9. willing to comply with all study assessments and adhere to the protocol schedule. 10. has an affiliation with a social security system.

inclusion criteria: 1. adult males and females ≥18 years and ≤80 years of age at the time of screening. 2. are hospitalised during the screening period with duration of hospitalisation prior to randomisation ≤48 hours. 3. have a diagnosis of covid-19 based on symptoms onset and positive sars-cov-2 rt-pcr test from nasopharyngeal swab. 4. viral load ≤ 30 ct 5. have at least one (1) of the following: 1. radiographic pulmonary infiltrates (ct scan), and/or 2. clinical assessment (evidence of rales/crackles on exam) and spo2 ≤94% on room air, and/or 3. requirement for supplemental oxygen. 6. if female, of non-childbearing potential or if of childbearing potential, be willing to commit to either sexual abstinence or use of at least 2 medically accepted, effective methods of birth control from screening through 2 months after last alisporivir dose. 7. if male, a willingness to refrain from donating sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, a willingness to use a condom in addition to having the female partner use a highly effective method of birth control from screening through 4 months after last alisporivir dose. 8. willing and able to provide written informed consent. 9. willing to comply with all study assessments and adhere to the protocol schedule. 10. has an affiliation with a social security system.